Biogen Inc. (NasdaqGS:BIIB) has been working with Goldman Sachs (GS) to find potential buyout targets and has a shopping list from the bank of potential acquisitions, STAT's Damian Garde and Adam Feuerstein reported, citing a person familiar with the matter. Goldman provided Biogen with a list of smaller biotech companies that might fit with the company's focus on neuroscience, including Biohaven Pharmaceutical (BHVN), Aurinia Pharmaceuticals (AUPH) and Amylyx (AMLX) and "the company's risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive," the biotech reporters said.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
216.1 USD | +0.61% | +7.00% | -16.48% |
04-30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
04-29 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.48% | 31.28B | |
-4.02% | 86.85B | |
+2.76% | 40.16B | |
+57.86% | 25.27B | |
-13.58% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-9.82% | 7.94B | |
+1.55% | 7.58B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Reportedly Works with Goldman to Explore Possible Acquisitions